CFTR and cystic fibrosis: This was of particular concern for CFTR bearing the variant c.2908G>C (predicted effect G970R), which was shown to respond well to ivacaftor in vitro, whereas individuals with CF carrying this variant that were entered into a clinical trial did not respond [28, 45].